Premium
In vivo localization of anti‐osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts
Author(s) -
Pimm M. V.,
Embleton M. J.,
Perkins A. C.,
Price M. R.,
Robins R. A.,
Robinson G. R.,
Baldwin R. W.
Publication year - 1982
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910300114
Subject(s) - monoclonal antibody , pathology , sarcoma , in vivo , antibody , immunoscintigraphy , scintigraphy , nude mouse , transplantation , medicine , cancer research , radioimmunotherapy , biology , immunology , microbiology and biotechnology
Monoclonal antibody 791T/36, (mouse IgG 2b ) to the human osteogenic sarcoma 791T was isolated from hybridoma supernatants or ascites fluid and labelled with radioiodine. Following injection into immuno‐deprived CBA mice with subcutaneous xenografts of human osteogenic sarcomas 791T, 788T and 20s, reactive antibody was detectable in the circulation and there was a preferential uptake into tumour tissue compared with muscle, bone or visceral organs. The tumour uptake of radioactivity correlated with the size of the xenograft, up to 20% of the total body counts being within the tumour. Autoradiography of tissue sections showed activity mainly within the subcapsular regions of the xenografts. There was no tumour localization of radio‐labelled normal IgG. Furthermore, with a colon carcinoma and a bladder carcinoma, both unreactive with the 791T/36 antibody, there was no localization of radiolabelled antibody in xenograft growths. With 791T/36 monoclonal antibody labelled with 131 I localization into 791T xenografts could be visualized by whole‐body gamma scintigraphy with computerized 99m Tc‐pertechnetate or 113m In‐indium chloride‐labelled blood pool subtraction. These studies demonstrate the potential of monoclonal antibody to a human tumour for in vivo localization both for diagnostic purposes and as a carrier for therapeutic agents.